Disseminated Fusarium infection in an immunocompromised host

被引:3
|
作者
Antony, SJ [1 ]
机构
[1] VANDERBILT UNIV,SCH MED,DEPT MED,DIV INFECT DIS,NASHVILLE,TN 37212
关键词
D O I
10.1111/j.1365-4362.1996.tb02983.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
A 42-year-old white man with acute myelomonocytic leukemia (AML) was admitted to the hospital for inductive chemotherapy. Four days after developing neutropenia, he developed fever, pain, and swelling of the third left toe. On examination, the foot was erythematous, swollen, and tender with onychomycosis and early gangrene of the toe. Examination of the eyes and heart were normal. Empiric treatment with vancomycin, piperacillin, cefetazidime, and fluconazole was started for presumed cellulitis. Despite the antibiotics, the toe required surgical drainage and distal partial amputation. Cultures from the blood and toe grew Fusarium spp. in 48 hours. Amphotericin B was started and fluconazole discontinued. In addition, he also developed multiple painful erythematous lesions with central necrotic areas over the rest of his body; these lesions also grew Fusarium. These lesions were not biopsied. The exit site of the Hickman catheter also became infected and on culture grew Fusarium. A computerized tomography (CT) scan of the abdomen was normal. The minimal inhibitory concentration (MIC) of amphotericin B at 48 and 72 hours was 4 μg per mL. The minimal fungicidal concentration (MFC) of amphotericin B at 48 and 72 hours was 4 μg per mL. Antifungal resistance was defined as > 1.56 μg per mL for amphotericin B and > 8 μg per mL for itraconazole. Amphotericin B treatment was continued for approximately 3 weeks with resolution of the lesions and the fungemia. On readmission, 4 weeks later for chemotherapy, he was placed on alternate-day amphotericin B. Monitoring of the blood levels was also started prior to discharge and continued for a total of 4 weeks. The patient remained well 8 weeks after discharge.
引用
收藏
页码:815 / 816
页数:2
相关论文
共 50 条
  • [31] AN UNUSUAL INFECTION IN AN IMMUNOCOMPROMISED HOST
    Phillips, N.
    Heazlewood, V
    Bazdar, S.
    Premaratne, G.
    Houston, A.
    Reilly, A.
    Baker, P.
    Waugh, J.
    INTERNAL MEDICINE JOURNAL, 2012, 42 : 20 - 20
  • [32] PULMONARY INFECTION IN THE IMMUNOCOMPROMISED HOST
    MCCABE, RE
    CURRENT OPINION IN INFECTIOUS DISEASES, 1991, 4 (03) : 380 - 385
  • [33] INFECTION CONTROL - THE IMMUNOCOMPROMISED HOST
    YOUNG, LS
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 1989, 10 (06): : 274 - 275
  • [34] Adenovirus Infection in the Immunocompromised Host
    Tebruegge, Marc
    Curtis, Nigel
    HOT TOPICS IN INFECTION AND IMMUNITY IN CHILDREN VI, 2010, 659 : 153 - 174
  • [35] FUNGAL INFECTION IN THE IMMUNOCOMPROMISED HOST
    UNDERMAN, AE
    SEMINARS IN RESPIRATORY MEDICINE, 1987, 9 (02): : 200 - 206
  • [36] STRONGYLOIDIASIS INFECTION IN AN IMMUNOCOMPROMISED HOST
    Ashangari, C.
    Siddiqui, S.
    Prakash, S.
    Khandheria, B.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2019, 67 (02) : 360 - 361
  • [37] Madurella infection in an immunocompromised host
    Satta, R
    Sanna, S
    Cottoni, F
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2000, 39 (12) : 939 - 941
  • [38] Prevention of infection in the immunocompromised host
    Risi, GF
    Tomascak, V
    AMERICAN JOURNAL OF INFECTION CONTROL, 1998, 26 (06) : 594 - 604
  • [39] Infection Control and the Immunocompromised Host
    Alothman, Adel
    SAUDI JOURNAL OF KIDNEY DISEASES AND TRANSPLANTATION, 2005, 16 (04) : 547 - 555
  • [40] Rotavirus infection in immunocompromised host
    Nakajima, H
    Kamisawa, T
    Nakagomi, T
    Nakagomi, O
    Nara, H
    GASTROENTEROLOGY, 2003, 124 (04) : A170 - A171